CRAM-A indicates IFN-γ-associated inflammatory response in breast cancer. Issue 2 (December 2015)

• Record Type: Journal Article
• Authors: Sarmadi, Parisa; Tunali, Gurcan; Esendagli-Yilmaz, Guldal; Yilmaz, Kerim Bora; Esendagli, Gunes
• Is Part Of: Molecular immunology. Volume 68:Issue 2(2015:Dec.) Part C
• Page Start: 692
• Page End: 698
• Publication Date: 2015-12
• Subjects: 7TM seven transmembrane-spanning -- ACKR atypical chemokine receptor -- B-CLL B-cell chronic lymphocytic leukemia -- CCRL C–C chemokine receptor-like -- CRAM chemokine receptor on activated macrophages -- EGFP enhanced green fluorescent protein -- ER estrogen receptor -- IFN interferon -- IHC immunohistochemistry -- IL interleukin -- MFI mean fluorescence intensity -- LPS lipopolysaccharide -- ORF open reading frame -- PCR polymerase chain reaction -- PR progesterone receptor -- RT reverse transcriptase -- TNF tumor necrosis factor; CCRL2 -- Immune response -- Breast cancer -- Inflammation -- Decoy receptor -- Atypical chemokine receptor; Immunochemistry -- Periodicals; Molecular biology -- Periodicals; Immunochemistry -- Periodicals; Allergy and Immunology -- Periodicals; Molecular Biology -- Periodicals; Immunochimie -- Périodiques; Biologie moléculaire -- Périodiques; Immunochemistry; Molecular biology; Periodicals; Electronic journals; 571.96
• DOI: 10.1016/j.molimm.2015.10.019
• Languages: English
• ISSNs: 0161-5890

Abstract

Highlights: The atypical chemokine receptor CCRL2 is constitutively expressed in breast cancer. CCRL2 expression is specific to malignant epithelium and inflammatory status. The rare isoform of CCRL2, CRAM-A is specifically upregulated upon IFN-γ exposure. CRAM-A marks inflammation and may serve as an immune modulator in breast cancer. Abstract: Atypical chemokine receptors (ACKRs) function as endpoint regulators of chemokine gradients. These non-signaling receptors that are transiently expressed under inflammatory conditions have critical roles in the control or maintenance of immune responses. Alternatively, here, CCRL2 (ACKR5) expression was determined to be constitutive in breast cancer cells. Increased amount of CCRL2 was also found in breast tumor tissues with high immune infiltration. Its expression was upregulated in the presence of pro-inflammatory cytokines, IL-1β, TNF-α, IL-6, and especially IFN-γ⋅ Moreover, an alternative transcript of CCRL2 gene, CRAM-A, was specifically expressed in a transient fashion under the influence of IFN-γ. CRAM-A expression was also positively correlated with the presence of IFN-γ mRNA in patient samples. CCRL2-associated chemotactic molecules, chemerin, CCL19 and CCL5, were also detected in cancer tissues and CCL5 mRNA level was correlated with that of CRAM-A and IFN-γ. Hence, in breast cancer, CRAM-A becomes specifically upregulated under inflammatory stimuli and may serve as a potential marker of immune response.